Sale of Significant Ownership Interest in AgeX to Juvenescence Limited (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Nov. 02, 2018	Aug. 30, 2018	Dec. 31, 2019	Nov. 28, 2018
Parent Company [Member] | Common Stock [Member]
Number of share sold			765,889
Number of shares owned			1,000,000	1,700,000
Common stock shares issued and outstanding percentage				4.80%
Juvenescence Limited [Member]
Number of share sold		14,400,000
Stock Purchase Agreement [Member] | Juvenescence Limited [Member]
Number of share sold		14,400,000
Sale of stock price per share		$ 3.00
Purchase price of shares		$ 43,200
Purchase price amount paid	$ 10,800
Indemnity cap		4,300
Proceeds from public offering		$ 50,000
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Series A Preferred Share [Member]
Debt conversion, price per share		$ 15.60
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Promissory Note [Member]
Purchase price amount paid		$ 21,600
Debt instrument interest rate		7.00%
Debt instrument maturity term		2 years
Debt instrument maturity date		Aug. 30, 2020
Interest income debt			$ 1,500
Promissory Note principal and accrued interest			$ 23,600
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Closing of Transaction [Member]
Purchase price amount paid		$ 10,800
Shareholder Agreement [Member]
Shareholder agreement description		Lineage and Juvenescence entered into a Shareholder Agreement, dated August 30, 2018, setting forth the governance, approval and voting rights of the parties with respect to their holdings of AgeX common stock, including rights of representation on AgeX's board of directors, approval rights, preemptive rights, rights of first refusal and co-sale and drag-along and tag-along rights for so long as either Lineage or Juvenescence continue to own at least 15% of the outstanding shares of AgeX common stock.